Allogene Director Receives 95,400 RSUs in Annual Board Compensation Grant

Elizabeth A. Barrett, Director of Allogene Therapeutics (ALLO), received a significant equity grant on June 18, 2025.

Rhea-AI Filing Summary

Elizabeth A. Barrett, Director of Allogene Therapeutics (ALLO), received a significant equity grant on June 18, 2025. The transaction involved the acquisition of 95,400 Restricted Stock Units (RSUs) with a $0 exercise price.

Key terms of the RSU grant:

• Vesting occurs in two equal semi-annual installments over one year from grant date
• Each RSU converts to one share of common stock
• Barrett elected to defer receipt of shares until either:
  • 30 days after Board separation
  • Company change in control

The grant represents part of the company's Non-Employee Director Compensation Policy. The filing was executed by Earl Douglas as Attorney-in-Fact on June 20, 2025.

Positive

• Director Elizabeth Barrett received a significant equity grant of 95,400 RSUs, demonstrating strong alignment with shareholder interests and commitment to long-term value creation

Negative

• None.

Insider Trade Summary

Grant/Award: 95,400 shares

Grant/Award 1 txn

Insider Barrett Elizabeth A.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	95,400	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 95,400 contracts (Direct)

Footnotes (1)

1. F1. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Ms. Barrett has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Restricted Stock Units (RSUs) did Elizabeth Barrett receive from ALLO on June 18, 2025?

Elizabeth Barrett received 95,400 Restricted Stock Units (RSUs) from Allogene Therapeutics (ALLO) on June 18, 2025. Each RSU represents a contingent right to receive one share of the Company's Common Stock.

What is the vesting schedule for Elizabeth Barrett's ALLO RSU grant?

The RSUs will vest in two equal semi-annual installments over a one-year period from the date of grant (June 18, 2025), subject to continued service through the vesting date.

When will Elizabeth Barrett receive the ALLO common stock from her RSU grant?

Barrett has elected to defer the receipt of Common Stock until the earlier of: (i) 30 days following her separation from the Board, or (ii) a change in control of the Company, pursuant to ALLO's Non-Employee Director Compensation Policy.

What is Elizabeth Barrett's role at ALLO according to the Form 4?

According to the Form 4 filing, Elizabeth Barrett serves as a Director of Allogene Therapeutics (ALLO), as indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2025 - 09:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barrett Elizabeth A.

(Last) (First) (Middle)

210 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Allogene Therapeutics, Inc. [ ALLO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	06/18/2025		A		95,400		(1)	(1)	Common Stock	95,400	$0	95,400	D

Explanation of Responses:

1. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Ms. Barrett has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company.

Remarks:

Exhibits: Power of Attorney

	/s/Earl Douglas, Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.